• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Clinical Data

Merck
Biotech

ESMO: Merck and Moderna post phase 3 cancer vaccine data early

While the primary endpoint hit approached analysts’ best-case scenario, the result was tempered by weaker-than-expected data on a secondary endpoint.
Nick Paul Taylor , Fraiser Kansteiner Oct 22, 2026 4:45pm
AbbVie

AbbVie posts phase 3 HS win but falls short of expectations

Oct 22, 2026 10:39am
Roche

Roche builds blockbuster case in MS as FDA decision approaches

Oct 21, 2026 9:30am
An arrow incrementally going up stairs before pointing straight up Blue background

Disc spins past FDA setback with ‘overwhelmingly positive’ data

Oct 19, 2026 8:00am
Monumental Sports  Entertainment Vanda Pharmaceuticals studio

Vanda pauses social anxiety program after failing phase 3 trial

Oct 15, 2026 2:25am
close-up image of an eye

Merck KGaA spinout iOnctura touts PI3K inhibitor in eye cancer

Oct 14, 2026 1:42pm

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings